Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.
Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide (Pomalyst) in multiple myeloma.
First, in the phase III randomized OPTIMISMM trial, the 3-drug regimen of pomalidomide with bortezomib (Velcade) and dexamethasone (PVd) was compared to the combination of bortezomib/dexamethasone. An 11-month progression-free survival (PFS) was found with the triplet regimen, versus 7.9 months in the control arm, according to Lonial.
These results are significant for these patients with early relapse. Lonial also notes that in the first patients to relapse, the PFS was at almost 20 months for the triplet regimen.
In the ELOQUENT-3 trial, patients with multiple myeloma were treated with either the triplet combination of elotuzumab (Empliciti) with pomalidomide and dexamethasone or pomalidomide/dexamethasone. The addition of elotuzumab improved PFS from about 3 months to over 10 months.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More